-+ 0.00%
-+ 0.00%
-+ 0.00%

ZENAS BIOPHARMA’S PARTNER, INNOCARE PHARMA, ANNOUNCES ACHIEVEMENT OF PRIMARY ENDPOINT IN PHASE 2B STUDY OF ORELABRUTINIB, A BTK INHIBITOR, FOR SYSTEMIC LUPUS ERYTHEMATOSUS

Reuters·12/15/2025 12:05:10

Please log in to view news